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DOI: http://dx.doi.org/10.1016/j.hemonc.2015.09.002OBJECTIVE/BACKGROUND: The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) group
has accumulated over 31 years of data and experience in hematopoietic stem cell transplantation (HSCT), par-
ticularly in hemoglobinopathies, severe aplastic anemia, inherited metabolic and immune disorders, in addition
to a wide array of hematologic malignancies unique to this region. A regional update in current HSCT trends is
highly warranted. We studied the trends of HSCT activities in World Health Organization-Eastern Mediterra-
nean (EMRO) region, surveyed by the EMBMT, between 2011 and 2012.
METHODS: Retrospective analysis of the survey data mainly of cumulative number of transplants, types of
transplants (autologous vs. allogeneic), types of conditioning such as myeloablative versus reduced intensity
was conducted. Also, trends in leukemias, hemoglobinopathies, severe aplastic anemia, inherited bone marrow
failure syndromes, amongst others were analyzed.
RESULTS: Twenty-one teams from nine EMRO countries reported their data (100% return rate) to the EMBMT
for the years 2011–2012, with a total of 3,546 first HSCT (1,670 in 2011; 1,876 in 2012). Allogeneic HSCT (allo-
HSCT) represented the majority (62%) in both years. The main indications for allo-HSCT were acute leukemias
(988; 46%), bone marrow failure syndromes (421, 20%), hemoglobinopathies (242; 11%), and immune defi-
ciencies (157; 7%). There was a progressive increase in the proportions of chronic myeloid leukemia cases
transplanted beyond first chronic phase (37 [7%] of all chronic myeloid leukemia cases in 2011 vs. 39
[29%] in 2012). The main indications for autologous transplants were multiple myeloma/plasma cell disorders
(510; 39%), Hodgkin lymphoma (311; 24%), non-Hodgkin lymphoma (259; 20%), and solid tumors (163; 12%).167
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special research report HEMATOPOIETIC STEM CELL TRANSPLANTATIONReduced intensity conditioning continued to show a progressive decrease over years (9.5% in 2011 vs. 7.9% in
2012), yet remained relatively low compared with contemporary practices in Europe published by EBMT. The
vast majority (91%) of allo-HSCT source was from sibling donors with continued dominance of peripheral blood
(64%) followed by bone marrow (33%).While umbilical cord blood transplants increased to 4% of allo-HSCT,
matched unrelated donor remained underutilized and there was no haplo-identical transplant reported. Large
centers with >50 HSCT/year, showed a continued increase in the total number of allo-HSCT over the past
2 years that may be related to capacity building issues and require further studies.
CONCLUSION: There is a discernable increase of HSCT rate in the EMRO region with a significant expansion
in utilization of cord blood transplants and allogeneic peripheral blood-HSCT as a valuable source. However,
further research of outcome data and the development of regional donor banks (cord blood and matched unre-
lated donors) may help to facilitate future planning to satisfy the escalating regional needs and augment collab-
oration within the EMBMT and globally.
KEYWORDS: Conditioning; EMRO; Hematopoietic stem cell transplantation; Stem cell sourceINTRODUCTIONHematopoietic stem cell transplantation(HSCT) is a well-established therapeuticprocedure for many hematologic and nonhe-
matologic disorders. The exponential increase in the
number of transplants performed yearly reflects the
expanding indications, as well as the growth of the
population and the awareness of HSCT among
physicians.
The Eastern Mediterranean Bone Marrow Trans-
plant registry (EMBMT) is a nongovernmental, non-
profit organization that was conceived in 2007 to
facilitate communication, exchange of knowledge,
and experience across the registered countries and
centers in the Eastern Mediterranean Region
(EMRO), as defined by the World Health
Organization.1,2
EMBMT has a mission to promote research and
collaborative studies across the organization and to
promote the best practices in all aspects of bone mar-
row (BM) transplant, including donor selection, stem
cell source and collection, conditioning, supportive
care, post-transplant follow-up, staff education, imple-
mentation of quality assurance programs, and stan-
dardization of the level of care.
The activity of EMBMT centers increases from
year to year as more patients are referred for HSCT
due to several factors including: broadening of the
indications for transplantation, increasing diagnostic
and therapeutic facilities, and increasing the availabil-
ity of matched donors with the establishment of alter-
nate donor programs. Improving the supportive care
also allowed raising of the upper age limit for
transplant.
The annual activity survey, describing the status of
HSCT in EMBMT, is an important tool to observetrends and to monitor advances in HSCT practice
in the EMRO region.
Organized reporting helps the registry, as well as
different participating teams, to observe changes in
the trends of HSCT and to evaluate factors associated
with such changes. This report is based on the 2011–
2012 survey data.MATERIALS AND METHODS
Data collection
Each participating team was requested to fill in a form
for uniform reporting of data from 2011 and 2012.
Reported data include indication, conditioning regi-
men, stem cell source, and donor type. Details of
reporting are already published in a previous
EMBMT report.3
Each team is responsible for applying quality con-
trol measures to assure validity of the entered data.
Data are mailed to the EMBMT office for final anal-
ysis. Collective and center-based data were further dis-
cussed with the relevant teams at the EMBMT
business meeting in 2013, and then a draft of the final
report was sent to each center before final publication.
The main reported data included cumulative num-
ber of transplants, transplant indications, donor type,
stem cell source, and intensity of conditioning such as
myeloablative versus reduced intensity conditioning
(RIC) versus others.Participating centers
A total of 21 centers from nine countries participated
in the 2011 and 2012 report. Only data from centers
performing more than five transplants per year for the
previous 3 years were included in this report. Partici-
pating teams and countries are listed in Table 1.Hematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015
Table 1. Transplant activities at different countries and centers in alphabetical order.
Country 2011 2012
Allo-SCT Auto-SCT UCBT Total Allo-SCT Auto-SCT UCBT Total
Algeria 111 82 0 193 120 52 1 173
Egypt 144 72 2 218 165 137 0 302
Iran 298 139 6 443 320 175 4 499
Jordan 53 42 2 97 56 54 3 113
Lebanon 45 65 0 110 40 91 0 131
Oman 21 7 0 28 19 5 0 24
Pakistan 61 8 0 69 63 6 0 69
Saudi Arabia 240 130 34 404 272 151 41 464
Tunisia 54 54 0 108 48 53 0 101
1027 599 44 1670 1103 724 49 1876
Note. Allo-SCT = allogeneic stem cell transplantation; Auto-SCT = autologous stem cell transplantation; UCBT = umbilical cord blood transplantation.
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Patient and transplant numbers
Wherever appropriate, “patient numbers” refer to the
number of patients receiving a first transplant and
“transplant numbers” refer to the total number of
transplants performed including first and subsequent
transplant.
Transplantation rates
Transplantation rates were defined as number of
HSCTs per 10 million inhabitants. They were com-
puted as previously defined for each year, disease indi-
cation, donor type, stem cell source, conditioning, and
country. Population data have been obtained from the
World Bank data base.4
Stem cell sources
Data were reported according to stem cell source into
BM, peripheral blood (PB), or umbilical cord blood.
Transplants with more than one source of stem cell
like BM stem cell transplant followed by a PB derived
stem cell boost were reported according to the source
of stem cells first infused.
Conditioning intensity
Conditioning regimens were reported as conventional
myeloablative or RIC as defined by EBMT.5 Condi-
tioning regimens reported as unknown or others
include unclear or incompletely reported conditioning
regimen.Hematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015RESULTS
General overview of 2011–2012 transplant activity in
EMBMT encompass twenty-one teams in nine
EMRO countries. All centers (100% return)
responded. The contacted teams are listed in Table 1
in alphabetical order according to country and city, as
well as transplant numbers for each center. Figure 1
shows the number of transplants for each country in
2011–2012.
Overall, in 2011–2012 there were 3,546 transplan-
tations reported by the participating teams, of which
2,130 (62.1%) were allogeneic and 1,311 (37.9%)
were autologous stem cell transplantations (auto-
SCTs). As compared with 2011, the total number
of transplants increased by 12.3% in 2012 (7% in allo-
geneic stem cell transplantation [allo-SCT] and 21%
in auto-SCT).
Transplants are grouped into eight main disease
categories, namely, leukemias (1,203 patients;
34.8%), lymphoproliferative disorders (1,156 patients;
33.4%), solid tumors (165 patients; 4.2%), BM failure
(421 patients; 12.2%), hemoglobinopathies (242
patients; 7%), primary immune deficiency (162
patients; 4.7%), inherited metabolic disorders (41
patients; 1.2%), and others (6 patients; 0.1%).
The transplant number increased in 2012 for most
indications and type of transplants. Between 2011 and
2012, the number of allo-SCTs increased from 1,027
to 1,103 transplants respectively, while the number of169
Figure 1. (A) Distribution of transplant numbers by country; (B) transplant number for each country in the Eastern Mediterranean Region in 2011–
2012. Note. EMRO = Eastern Mediterranean Regional Office.
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respectively.
Figures 2 and 3 show the numbers of patients
receiving auto-SCT and allo-SCT, respectively, by
disease indication for the years 2011–2012.
Transplant rates
Transplant rates differed substantially between partic-
ipating EMRO countries. The differences were
related to all types of SCT.
The transplant rates were also variable among dif-
ferent teams; with some teams performing only autol-
ogous transplants and others doing only related donor
transplants.
The median number of transplants during 2011–
2012 was 47 transplants per center per year (range,
4–373).Figure 2. Distribution of different indications for autologous stem cell tran
SCT = autologous stem cell transplantation; NHL = non-Hodgkin lymphomaTransplant rates per 10 million population remain
very low when compared with the rates in EBMT
data.6,7
It varied in 2011 from 0.3 per year in Pakistan to
25 per year in Lebanon, with a median of 9.2 per
10 million per year.
Figure 4 show the transplant rate per 10 million
inhabitants for each country in the EMRO.
Patients with leukemias were mainly treated with
allo-SCT (96.1%). Patients with lymphoproliferative
disorders were treated predominantly with auto-
SCT (93.4%). Patients with solid tumors were almost
exclusively treated with autologous HSCT (99–
100%). By contrast, patients with BM failure, hemo-
globinopathies, immunodeficiency disorders, or
inborn errors of metabolism, almost exclusively
underwent allo-SCT (100%).splantation in 2011–2012. Note. AML = acute myeloid leukemia; Auto-
.
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Figure 3. Distribution of different indications for allogeneic stem cell transplantation in 2011–2012. Note. ALL = acute lymphoblastic leukemia;
AML = acute myeloid leukemia; CLL = chronic lymphocytic leukemia; CML = chronic myeloid leukemia; JMML = juvenile myelomonocytic leukemia;
MPD = myeloproliferative disease; NHL = non-Hodgkin lymphoma.
Figure 4. Transplant rate per 10 million inhabitants for each country in the Eastern Mediterranean Regional Office (EMRO) Region.
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As previously reported in the EMBMT area, the prev-
alence of matched family donors is relatively high.8
This is in part due to relatively higher family size
and consanguinity where a restricted pool of genes
is being inherited.
Most of the donors for allo-SCT were human leu-
kocyte antigen matched family members (936 [91%]
patients in 2011 and 1,009 [91%] patients in 2012).
Alternate donor transplants were performed in only
45 patients and 59 patients (4% and 5% in 2011
and 2012, respectively).
Most alternate donor transplants were done for
patients with acute leukemia (33% and 47%, respec-
tively) and primary immune deficiency syndromes
(16.5% and 19%, respectively). However, 16% and
7% of alternate donor transplants were offered to
patients with BM failure in 2011 and 2012, respec-
tively. Figure 5 shows the different donor types in
2011 and 2012.
The increase in alternate donor transplant was
mainly for patients with acute leukemia beyond first
complete remission at time of transplant and primary
immune deficiency. Umbilical cord blood is still the
main source of stem cells when alternate donor is con-Hematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015cerned, representing 89% and 82% of alternate donor
transplant in 2011 and 2012, respectively. Most
umbilical cord blood transplantations (UCBTs) were
done from unrelated donors. Only four (9%) and
three (5%) patients of all UCBTs were from related
donors in 2011 and 2012, respectively. The other
UCBTs were from unrelated donors.
Matched unrelated donor transplants increased
from 3 transplants during 2011 to 13 transplants in
2012 (333.3%).
Figure 6 represents the number and indications of
alternate donor transplant in 2011–2012.
All auto-SCTs done in 2011 were from PB stem
cells. In 2012, only one out of 724 auto-SCTs was
from BM derived stem cells.
In allo-SCT, PB was the dominant source of stem
cells in 2011 (59%); there was a trend towards
increased utilization of PB stem cells in 2012 (68%)
and a decrease in BM as a source of stem cells.
Figures 7 and 8 represent the stem cell source in
2011 and 2012.
The choice of stem cell source differed much by
indication for all types of allogeneic HSCT. PB
remained the preferred source of stem cells for most
cases of allogeneic transplants. In 2011, BM was the171
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main source of stem cell for allo-SCT for marrow fail-
ure syndromes including severe aplastic anemia;
(107 of 194 patients [55%]). However, in 2012 there
was a trend toward utilizing PB as the main source of
allo-SCT for the same indication, with 124 of 227
transplants (55%) being of PB source.
Although the number of alternate donor trans-
plants had increased, the percentage of the total trans-
plant number remained at 4%.Figure 6. Stem cell source and indications of alternate donor transplant
myeloid leukemia; CML = chronic myeloid leukemia; MUD = matched
transplantation.
Figure 7. Stem cell source for allogeneic hematopoietic stem cell transp
transplantation; BM = bone marrow; PB = peripheral blood.
Figure 5. Different donor types in 2011 and 20Indications for allogeneic stem cell transplant in
2011–2012
On review of the allo-SCTs performed between 2011
and 2012, overall, there was no major change in the
performance of transplants for most of the indica-
tions. In general, the changes in trends for allo-SCT
were much less obvious than in auto-SCT.
Acute leukemia including myeloid and lymphoid
leukemia in first complete remission was the mostin 2011–2012. Note. ALL = acute lymphoblastic leukemia; AML = acute
unrelated donor; SAA = severe aplastic anemia; SCT = stem cell
lantation in 2011. Note. Allo-SCT = allogeneic hematopoietic stem cell
12. Note. MUD = matched unrelated donor.
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Figure 8. Stem cell source for allogeneic hematopoietic stem cell transplantation in 2012. Note. Allo-SCT = allogeneic hematopoietic stem cell
transplantation; BM = bone marrow; PB = peripheral blood.
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(33.2% and 30.6%, respectively). Acute leukemia
beyond first complete remission was a less frequent
indication for allo-SCT in 2011–2012 (14.9% and
14.3%, respectively).
Other common indications for allo-SCT in 2011–
2012 include: marrow failure syndromes (18.9% and
20.6%, respectively), hemoglobinopathies, particularly
thalassemias, (12% and 10.8%, respectively), and pri-
mary immunodeficiency syndromes (7.3% and 7.4%,
respectively).
Less common indications that contributed to <5%
of all allo-SCTs in 2011–2012 include chronic mye-
loid leukemia either in chronic phase (2.6% and
1.9%, respectively), or at more advanced stage (0.9%
and 1.6%, respectively), myelodysplastic syndrome
(2.7% and 3.7%, respectively), myeloproliferative
disorder including juvenile myelomonocytic leukemia
(0.68% and 1.5%, respectively), lymphoproliferative
disorders including myeloma, non-Hodgkin
lymphoma (NHL), and Hodgkin lymphoma (3.1%
and 4%, respectively), and hereditary metabolic
disorders (2.05% and 1.8%, respectively).
Figure 3 represent the distribution of various indi-
cations of allo-SCT patients in the EMBMT data
base.
Indications for auto-SCT in 2011–2012
Like the previous years, auto-SCT was less frequently
performed than allo-SCT. There was a 21% increase
in number of auto-SCTs in 2012 compared with
2011. The most frequent indications for auto-SCT
in 2011 and 2012 were plasma cell dyscrasias (40%
and 37.7%, respectively), Hodgkin’s disease (26.4%
and 21.4%, respectively), NHL (16.5% and 22.4%,
respectively), and solid tumors, mainly neuroblastoma
(11.1% and 13.5%, respectively).Hematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015The most significant increase in transplant activity
was an increase in auto-SCT for NHL (64.2%), for
solid tumors, mainly neuroblastoma (46%), and for
multiple myeloma (13.4%). Figure 2 represent the
distribution of auto-SCT patients in the EMBMT
data base.
Conditioning
Conventional myeloablative conditioning was the
most utilized throughout 2011–2012 (63.9% and
63.3%, respectively). RIC was used in 9.5% of all
allo-SCTs in 2011. There was a trend towards less
utilization of RIC in 2012 both in number (98 vs.
87) and in percentage (9.5% vs. 7.9%). Only 9 out
of the 21 participating centers reported using RIC
allo-SCT.
In RIC-SCT, the stem cell source was PB (74%
and 61%), BM (12% and 21%), and cord blood
(11% and 6.7%) in 2011 and 2012, respectively.
In 2012, the reported number of unknown condi-
tioning/others decreased to 18 versus 28 in 2011
(1.5% vs. 3.5%) reflecting improvement in the accu-
racy of reporting and completion of details of condi-
tioning regimens.DISCUSSION
The need for SCT will continue to grow, as will
the need for improvements in all the transplant
related activities from donor selection, availability
of alternate donors, conditioning regimen, and sup-
portive care.
The challenges imposed by population growth as
well as the advances in transplantation practice in gen-
eral are stimulating EMBMT centers to create uni-
form policies to optimize resource utilization to face
such challenges.173
Table 2. Transplant rate
Country
Algeria
Egypt
Iran
Lebanon
Oman
Pakistan
Saudi Arabia
Tunisia
Jordan
174
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The EMBMT activity survey has been conducted
regularly since EMBMT was established in 2007.
The 2011–2012 survey had reported 3,546 patients
with a trend to an additional increase by 12.3% in
2012.
Although the annual increase in transplant rate is
double that observed in EBMT data (6%),6 yet the
transplant rate per 10 million inhabitants’ remains
significantly lower. We have previously reported that
the transplant activity in the region between 1990
and 2010 is increasing at a rate greater than the pop-
ulation increase; furthermore, the transplant activity
in the region is rising at a rate greater than that
reported for the EBMT.9 In the nine EMBMT coun-
tries with a collective population of 420 million in
2011 that increased to 427 million in 2012,2 1,670
and 1,876 SCTs were performed respectively corre-
sponding to 39.7 per 10 million and 43.9 per 10 mil-
lion population.
Transplantation rates per 10 million inhabitants
for auto-SCT were 14.1 and 16.8 in 2011–2012
respectively, remaining significantly lower than that
reported in EBMT region with a median of auto-
SCT of 151 transplants per 10 million inhabitants.
The same holds true for allo-SCT with a rate of
24.3 and 25.7 per 10 million inhabitants for the same
period compared with a median of 109 in the EBMT
region.7
The increase in transplant rates were variable
among different indications; transplants for some
indications continued to increase while others did
not (see Table 2).s per 10 million of different EMRO countries.
2011
Population size No. of transplant % per 10 million
37,762,962 193 5.111
79,392,466 218 2.721
75,424,285 443 5.794
4,382,790 110 25.098
3,024,774 28 9.257
176,166,353 69 0.392
27,761,728 404 13.328
10,673,800 108 10.118
6,181,000 97 15.370The most notable growth of transplant rate was in
auto-SCT for NHL and myeloma reflecting the suc-
cess of the newer therapeutic agents in rendering
more patients eligible for transplant.
Of interest is the continued sharp decrease of
transplant number for chronic myeloid leukemia
patients from the main indication for allo-SCT two
decades ago to 2.2% in 2011–2012, where tyrosine
kinase inhibitor successfully eliminated the need for
SCT for most chronic myeloid leukemia patients.
Human leukocyte antigen matched family donors
remain the dominant modality of allo-HSCT. Large
family sizes and high rates of population growth sig-
nificantly contribute to the high availability of related
family donors in the EMBMT region.8
Unrelated donor transplant rates remain signifi-
cantly lower than in the western world and almost
restricted to UCBT. Very few matched unrelated
donor transplants were performed in 2011–2012.
Lack of alternate donor programs, national donor
registries, and regional donor registries in the
EMBMT region limits the utilization of this stem
cell source.
The number of patients undergoing cord trans-
plantation has increased as a consequence of increas-
ing experience of this technique and availability of
evidence based data supporting its use. The number
of cord blood banks in the EMRO region remains
small. The establishment of more cord blood banks
will help in improving the availability of this alternate
transplantation modality for patients with no matched
related donors.2012
Population size No. of transplant % per 10 million
38,481,705 173 4.470
80,721,874 302 3.741
76,424,443 449 6.477
4,424,888 131 29.605
3,314,001 24 7.242
179,160,111 69 0.385
28,287,855 464 14.953
10,777,500 101 9.371
6,318,000 113 17.411
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The practice of haploidentical transplant is still in
its infancy in the EMRO region with no reported
cases during both 2011 and 2012.
There is a trend towards more use of PB as a stem
cell source even for patients with SAA and
non-neoplastic hematologic disorders in spite of the
concerns of higher risk for chronic graft-versus-host
disease associated with PB as a stem cell source.10,11
PB was the stem cell source for 34.3% of
allo-SCTs for SAA in 2011 compared with 56.6%
in 2012.
In many developing countries, the use of PB in
aplastic anemia as well as non-neoplastic hematologic
disorders is favored in order to promote fast engraft-
ment and independence from platelet and red cell
transfusions, as well as infections and is likely to bal-
ance the morbidity risk of increase graft-versus-host
disease, especially in the context of a late diagnosis.
In total, PB was the main stem cell source in all
types of allo-SCT (72.6% and 81.7% in 2011 and
2012, respectively). As noted above, rapid engraft-
ment and immune reconstitution observed with PB
transplants as well the large proportion of hemato-
logic malignancies among the transplant indications
make it the preferred stem cell source.Hematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015Although there is improved reporting of cases by
participating centers as reflected by less number of
conditioning regimens marked as “others” or
“unknown”, there was a trend towards less utilization
of RIC transplants in 2012. As we do not have the
data of indications of RIC-SCT at different centers,
we cannot explain the decrease in both number and
percentage of RIC transplants in 2012.
It would be of interest to report on the outcome
data, measuring the effect of transplant rates at differ-
ent centers on the outcome, but unfortunately these
data are currently not included in the annual survey.
Again, some other important data are missing from
the survey including data on additional cellular thera-
pies like donor lymphocyte infusion and
mesenchymal-SCTs. Further modification of the sur-
vey to capture more outcome data in the coming years
will make the report more informative and will help
transplant authorities in planning and adopting more
optimum policies to satisfy the growing need for
SCTs in the region of EMRO.CONFLICTS OF INTEREST
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